Abstract
The G protein-coupled receptor GPR139 is a key target for neuromodulation, with agonists currently in clinical trials for treating cognitive impairment and schizophrenia. Although classified as an orphan receptor, GPR139 is activated by amino acids like L-Trp and L-Phe, primarily triggering the Gq/11 pathway. It acts as a regulator of μ-opioid and dopamine signaling in the central nervous system. Until now, the structural basis for its ligand recognition and G protein coupling remained unknown. This paper presents cryo-electron microscopy (cryo-EM) structures of GPR139 in complex with the agonist JNJ-63533054 and various G proteins (miniGs/q and Gi), including rare intermediate states bound to GDP and GTP.
Introduction
GPR139 is a Class A GPCR highly expressed in the brain, where it modulates critical neurotransmitter systems. Its therapeutic potential for treating the negative symptoms of schizophrenia has made it a high-priority target. However, the lack of structural data has hindered our understanding of how it recognizes ligands and selects between different intracellular signaling pathways. Most GPCR structures are captured in a nucleotide-free state; this study addresses that gap by capturing the receptor in physiologically relevant intermediate states bound to GDP and GTP.
Methods
The research team utilized high-resolution cryo-EM (3.2 Å to 3.8 Å) to solve the structures of GPR139. They employed several stabilization techniques, including the use of a Xylanase fusion protein and specific mutations like S62(2x39)V. To observe the G protein activation cycle, they used chimeric miniGs/q and heterotrimeric Gi proteins, adding GDP or GTP before sample freezing. These structural models were further validated using Bioluminescence Resonance Energy Transfer (BRET) functional assays and Molecular Dynamics simulations.
Key Structural Insights
The R244 Anchor and Binding Pocket
A defining feature of the GPR139 binding pocket is the presence of Arginine 244 (R244 at position 6x51), a residue that is typically hydrophobic in other Class A GPCRs. R244 acts as a critical anchor, forming hydrogen bonds with the agonist. Mutating this residue almost entirely abolishes receptor activity, highlighting its functional importance. The study also identified a "negatively charged wall" of residues that likely funnels ligands into the binding pocket via electrostatic interactions.
Ligand Pose Shifting and Activation Intermediates
One of the most significant findings is that the agonist JNJ-63533054 adopts different orientations, or "poses," depending on the G protein it is coupled with and the presence of nucleotides. This suggests a bidirectional allosteric communication where the state of the G protein influences the shape of the drug-binding pocket. By capturing GDP- and GTP-bound states, the authors visualized the mechanical movement of the G protein's α5 helix as it inserts into the receptor core during activation.
Discussion and Future Directions
This study provides a comprehensive structural blueprint for GPR139, explaining its unique ligand recognition mechanism and pathway selectivity. While the use of a surrogate agonist (JNJ-63533054) provided high-resolution data, future work is needed to experimentally resolve the binding of endogenous ligands like L-Tryptophan. The discovery of intermediate nucleotide-bound states provides a new template for understanding the universal mechanics of GPCR-G protein signaling, which could lead to more precise drug design for CNS disorders.
Summary updated